AI in Healthcare
The latest on artificial intelligence transforming medicine
News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.
LenioBio and Twist Bioscience Forge an AI Drug Discovery Collaboration Around Better Molecular Models
LenioBio and Twist Bioscience are partnering to support AI drug discovery model development, a sign that the field still depends heavily on high-quality biological data and experimental systems. The collaboration highlights a core truth of AI in biotech: better models require better inputs, and better inputs require partnerships.
AI Designs Are Reaching the Lab Bench, Not Just the Leaderboard
Drug-target AI is moving from benchmark competitions into preclinical testing, a sign the field is maturing beyond paper claims. The crucial question now is whether these designs can survive the harsher reality of experimental biology.
New Data Suggests AI Models Can Match Human Accuracy, But Reasoning Remains the Bottleneck
A recent report says AI tools can match human accuracy in some tasks while still struggling with reasoning. That split is especially important in healthcare, where correctness depends on more than pattern recognition. The finding helps explain why many medical AI systems perform well in narrow benchmarks but still falter when clinical context becomes messy or ambiguous.
OpenAI’s Life Sciences Launch Intensifies the Battle for Drug Discovery AI
OpenAI’s new life sciences model has drawn immediate attention because it pushes the company into one of the most commercially attractive corners of AI. The launch underscores how rapidly model developers are moving to claim the drug discovery market before it hardens around a few dominant platforms.
OpenAI Takes on Google in the AI Drug Discovery Market
OpenAI’s new model aimed at drug discovery highlights how quickly the AI labs are moving into biotech. The competitive backdrop is no longer theoretical: model makers are now openly targeting the same scientific workflows that cloud and pharma players want to own.
Tempus and Daiichi Sankyo Push AI Upstream Into ADC Design
Tempus and Daiichi Sankyo are teaming up on AI models for antibody-drug conjugate development, extending AI’s role from biomarker work into the design logic of one of oncology’s hottest drug classes. The collaboration matters because ADCs are complex, multimodal products where better target, linker, payload, and patient-selection decisions could materially improve success rates.
New AI Model Highlights a Familiar Truth in Drug Discovery: Better Models Matter Only if Experiments Keep Up
A report on an AI model that accelerates therapeutic drug discovery points to ongoing technical progress in model-guided candidate generation and prioritization. But its broader significance is as a reminder that the field’s central bottleneck is increasingly the translation of computational gains into experimental throughput and validated biology.
New AI Model Predicts How Chemicals Alter Gene Expression
Researchers have developed an AI model that predicts chemical effects on gene expression, a capability that could speed early-stage drug discovery and toxicology screening. If robust, such models could help researchers prioritize compounds before expensive laboratory profiling begins.
How this works
Discover
An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.
Structure
The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.
Publish
Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.